Prelude Therapeutics Gains FDA Clearance for PRT13722
WILMINGTON, Del. — September 10, 2026 Prelude Therapeutics Incorporated announced that the U.S. Food and Drug Administration (FDA) has...
Precision Oncology
Advertisement
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Verastem Oncology Advances VS-7375 Across KRAS G12D Cancers
BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...
Faeth Therapeutics Highlights PIKTOR Strategy Ahead of Phase 2 Data
AUSTIN, Texas — September 8, 2026 Faeth Therapeutics announced plans to host a virtual key opinion leader (KOL) event...
Medicus Pharma Advances Precision Oncology Strategy With CD228V
PHILADELPHIA, Pennsylvania — September 8, 2026 Medicus Pharma Ltd. announced a strategic transformation into a precision oncology-led biotechnology company,...
Advertisements
Caris Life Sciences Promotes Caris Detect for Cancer
Irving, Texas, U.S, September 8, 2026 Caris Life Sciences, an artificial intelligence and precision medicine company, has launched a...
Guardant Health Wins FDA Approval for Breast Cancer CDx
Palo Alto, California — September 4, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has...
Akeso Reports Ivonescimab OS Benefit in HARMONi-2
Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...
Styx and ZoeNCure Advance Next-Generation ADCs to Clinic
San Diego, California, USA, September 1, 2026 Styx Biotechnologies Inc., a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for...
Guardant Health Expands Shield CRC Screening Coverage
PALO ALTO, Calif., Sept. 1, 2026 Guardant Health announced that its Shield blood test for colorectal cancer (CRC) screening...
Advertisement
